Protagonist Therapeutics Intrinsic Value Calculation – Protagonist Therapeutics Shares Rise 4.6% on Friday
June 19, 2023
☀️Trending News
On Friday, Protagonist Therapeutics ($NASDAQ:PTGX), Inc. saw an impressive increase in their share prices, going up 4.6%. This is great news for the company, which is a biopharmaceutical firm that focuses on developing and commercializing small molecule drugs. They use their proprietary platform to identify, develop and commercialize peptide-based therapeutics which are designed to target different diseases, such as inflammatory bowel disease, anemia, and hemophilia. Since then, the company’s stock has been steadily increasing and the jump on Friday is a sign of positive sentiment from the market about the company’s future prospects.
Protagonist Therapeutics is currently engaging in several clinical trials for its drug candidates and has partnered with many leading biotechnology and pharmaceutical companies. The Friday surge in their stock prices is therefore a testament to the continued success of the company and a promising outlook for their future prospects. Investor confidence in Protagonist Therapeutics has been growing steadily and the stock looks like it’s only going up from here.
Analysis – Protagonist Therapeutics Intrinsic Value Calculation
At GoodWhale, we have conducted an in-depth analysis of PROTAGONIST THERAPEUTICS’s wellbeing. Using our proprietary Valuation Line, we have determined that the fair value of PROTAGONIST THERAPEUTICS shares is approximately $14.4. However, PROTAGONIST THERAPEUTICS stock is currently traded at $25.6, which is overvalued by 78.2%. This suggests that there is significant potential for PROTAGONIST THERAPEUTICS if they can make the correct decisions and take the right steps to increase their value. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Protagonist Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 0.86 | -140.19 | -16319.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Protagonist Therapeutics. More…
| Operations | Investing | Financing |
| -108.14 | 91.47 | 18.84 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Protagonist Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 239.86 | 23.69 | 4.19 |
Key Ratios Snapshot
Some of the financial key ratios for Protagonist Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -28.2% | – | -16566.1% |
| FCF Margin | ROE | ROA |
| -12681.3% | -41.3% | -37.1% |
Peers
The company’s competitors include LogicBio Therapeutics Inc, Landos Biopharma Inc, and IO Biotech Inc.
– LogicBio Therapeutics Inc ($NASDAQ:LOGC)
LogicBio Therapeutics Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases. The company’s lead product candidate is LB-1001, which is in clinical development for the treatment of adenosine deaminase severe combined immunodeficiency (ADA-SCID). The company has a market cap of $67.57 million and a return on equity of -82.33%. LogicBio Therapeutics is headquartered in Boston, Massachusetts.
– Landos Biopharma Inc ($NASDAQ:LABP)
Landos Biopharma Inc is a clinical-stage biopharmaceutical company dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
Landos Biopharma Inc has a market cap of 14.4M as of 2022, a Return on Equity of -64.92%. The company is dedicated to developing and commercializing first-in-class oral therapeutics for the treatment of autoimmune diseases. The company’s lead product candidate, BT-11, is a first-in-class, orally-active, selective inhibitor of losartan-sensitive, non-competitive alpha9beta1 integrin. BT-11 is being developed as a novel, disease-modifying therapy for patients with primary sclerosing cholangitis (PSC), a chronic, progressive, orphan liver disease. PSC is characterized by inflammation and fibrosis of the bile ducts, which can lead to liver failure and death. There are currently no FDA-approved treatments for PSC. Landos is currently enrolling patients in a Phase 2 clinical trial of BT-11 in patients with PSC. The company has demonstrated proof-of-concept in a Phase 2a clinical trial in patients with relapsing remitting multiple sclerosis (RRMS), an autoimmune disease of the central nervous system. Landos is currently preparing to initiate a Phase 2b clinical trial of BT-11 in patients with RRMS.
– IO Biotech Inc ($NASDAQ:IOBT)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule drugs to treat serious unmet medical needs, primarily in oncology. The company has a market capitalization of $72.04 million and a negative return on equity of 20.77%. Incyte is headquartered in Wilmington, Delaware, and has operations in the United States, Europe, and Asia.
Summary
Investing analysis on Protagonist Therapeutics, Inc. has been positive lately, with their shares rising 4.6% on Friday. The company is developing novel peptide-based drugs for the treatment of serious diseases, such as inflammatory bowel disease, genetic diseases, and cancer; all of which have high unmet needs. Investors seem to be optimistic about the progress of the company’s research and development, and the potential for the development of safe and effective drugs.
As the company continues to advance their pipeline of peptide-based drugs and gain clinical achievements, they could become a leader in the biotech industry. With positive investor sentiment surrounding Protagonist Therapeutics, Inc., investors may find it a good time to enter the market.
